People with rare diseases often face unique challenges due to the complexity of their conditions and lack of information about them, and we recognize that unique challenges call for creative solutions. For this reason, Alnylam is dedicated to helping people affected by rare diseases by creating opportunities and supporting programs that drive meaningful impact in rare disease communities around the world.

Rare disease patients often endure a long diagnosis journey, suffer from suboptimal care and need accurate disease information. Advocacy for Impact Grants is a global program, and Alnylam recognizes that unmet needs will differ across diverse communities and geographies. We encourage patient advocacy groups from around the world to apply with new projects targeted to specifically meet the unique or special needs of their own communities.

Advocacy for Impact Grants is a global competitive grants program that aims to inspire patient advocacy groups to develop solutions to address critical unmet needs in the rare disease communities they serve. At our core, we value and understand how exploring and developing new ideas has the potential to create high-impact initiatives that are a catalyst for change. Therefore, we are seeking opportunities to provide patient advocacy groups with the resources to be creative and to bring new projects to fruition.

In its second year, Advocacy for Impact Grants will continue to focus on the ATTR amyloidosis, acute hepatic porphyria and primary hyperoxaluria type 1 communities from around the world.

The program will recognize and fund projects, each in an amount up to $50,000 USD, that aim to:

- Increase disease awareness and access to diagnosis
- Offer education to patients, families, caregivers, healthcare providers and/or public
- Improve patient care

All projects outlined in applications must be new projects that have not previously been implemented by the group.
WHO IS ELIGIBLE?

Advocacy for Impact Grants will consider applications from patient advocacy groups around the world. Patient advocacy groups must have a charitable status in their country and may only submit one application per year. Projects may be a collaboration between two patient advocacy groups, but this is not a requirement.

Patient advocacy groups may serve other patient communities, but projects outlined in applications must be focused on the ATTR amyloidosis, acute hepatic porphyria and/or primary hyperoxaluria type 1 communities. Please note that applications solely focused on research or for registries will not be considered as part of this program.

Recipients of the 2018 Advocacy for Impact Grants must wait one application cycle before applying again, and therefore are not eligible to apply for this year’s cycle. Alnylam reserves the right to provide no funding if no applications are received that fully meet the eligibility and review criteria.

HOW TO APPLY

Applications must describe new projects that impact the ATTR amyloidosis, acute hepatic porphyria and/or primary hyperoxaluria type 1 patient communities. Applications will be accepted between Nov 19, 2019 and Jan 3, 2020 and may be submitted in any language. An independent translation company will translate all applications into English prior to evaluation.

To apply, please visit our website to download an application. Completed applications should be submitted via email to AdvocacyForImpact@alnylam.com by 11:59pm EST on Jan 3, 2020.

For more information on the eligibility criteria, review and submission process, please visit the website and download the Application Guide. Grant recipients will be announced in mid-2020 and projects must be completed within a year and a half after funds are provided.

REVIEW CRITERIA

A review committee comprised of a mix of both external and internal experts will review applications and determine grant recipient(s) based on:

- Clear identification of an unmet need
- Plan of execution
- Level of impact within the target community
- Strong evaluation strategy

Applications are reviewed based on their own merit and are reviewed independently from one another.

For more information, please visit our website or reach out to AdvocacyforImpact@alnylam.com.

ABOUT ALNYLAM

At Alnylam, we are dedicated to helping patients in rare disease communities. With a bold vision to turn scientific possibility into reality, we are leading the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of patients who have limited treatment options.

© 2019 Alnylam Pharmaceuticals, Inc.
675 West Kendall Street
Cambridge, MA 02142 | USA